Back to results
US 12,643,909 B2Granted
Bivalent ligands to understand dimerization of the mu opioid receptor and the chemokine receptor CCR5 in neurological disorders
AssigneeVirginia Commonwealth University
InventorYan Zhang
Life of this patent
Estimating the term…
Abstract
Bivalent ligands which bind to MOR-CCR5 heterodimers are provided. The bivalent ligands comprise two discrete pharmacophores, naltrexone and maraviroc, linked by a spacer and bind to MOR-CCR5 heterodimers, e.g. at the surface of a cell. The bivalent ligands are useful in assays to detect MOR-CCR5 heterodimers, as therapeutic agents to prevent and/or treat diseases characterized by the presence of MOR-CCR5 heterodimers.
Claims17
A bivalent ligand having Formula I:
- where L is
- where n ranges from 0 to 12, * indicates a point of attachment to naltrexone;
- and
- ** indicates a point of attachment to maraviroc;
- or
- where n ranges from 0 to 12, * indicates a point of attachment to naltrexone;
- and
- ** indicates a point of attachment to maraviroc;
- or
- where n ranges from 0 to 12, * indicates a point of attachment to naltrexone;
- and
- ** indicates a point of attachment to maraviroc;
- or
- where n ranges from 0 to 12, * indicates a point of attachment to naltrexone;
- and
- ** indicates a point of attachment to maraviroc;
- or
- where n ranges from 0 to 12, * indicates the point of attachment to naltrexone;
- and
- ** indicates the point of attachment to maraviroc.
17 more elements
Dependencies are inferred from the claim text.